Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1996 Aug;49(8):620–622. doi: 10.1136/jcp.49.8.620

Immunisation policies--successes, failures and the future.

E Miller 1
PMCID: PMC500601  PMID: 8881908

Full text

PDF
620

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aaby P., Knudsen K., Whittle H., Lisse I. M., Thaarup J., Poulsen A., Sodemann M., Jakobsen M., Brink L., Gansted U. Long-term survival after Edmonston-Zagreb measles vaccination in Guinea-Bissau: increased female mortality rate. J Pediatr. 1993 Jun;122(6):904–908. doi: 10.1016/s0022-3476(09)90015-4. [DOI] [PubMed] [Google Scholar]
  2. Agol V. I., Drozdov S. G. Russian contribution to OPV. Biologicals. 1993 Dec;21(4):321–325. doi: 10.1006/biol.1993.1091. [DOI] [PubMed] [Google Scholar]
  3. Brown D. W., Ramsay M. E., Richards A. F., Miller E. Salivary diagnosis of measles: a study of notified cases in the United Kingdom, 1991-3. BMJ. 1994 Apr 16;308(6935):1015–1017. doi: 10.1136/bmj.308.6935.1015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Gay N. J., Hesketh L. M., Morgan-Capner P., Miller E. Interpretation of serological surveillance data for measles using mathematical models: implications for vaccine strategy. Epidemiol Infect. 1995 Aug;115(1):139–156. doi: 10.1017/s0950268800058209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Gindler J. S., Atkinson W. L., Markowitz L. E. Update--the United States measles epidemic, 1989-1990. Epidemiol Rev. 1992;14:270–276. doi: 10.1093/oxfordjournals.epirev.a036090. [DOI] [PubMed] [Google Scholar]
  6. Morris W., Steinhoff M. C., Russell P. K. Potential of polymer microencapsulation technology for vaccine innovation. Vaccine. 1994 Jan;12(1):5–11. doi: 10.1016/0264-410x(94)90003-5. [DOI] [PubMed] [Google Scholar]
  7. RAUH L. W., SCHMIDT R. MEASLES IMMUNIZATION WITH KILLED VIRUS VACCINE. SERUM ANTIBODY TITERS AND EXPERIENCE WITH EXPOSURE TO MEASLES EPIDEMIC. Am J Dis Child. 1965 Mar;109:232–237. doi: 10.1001/archpedi.1965.02090020234007. [DOI] [PubMed] [Google Scholar]
  8. Rabinovich N. R., McInnes P., Klein D. L., Hall B. F. Vaccine technologies: view to the future. Science. 1994 Sep 2;265(5177):1401–1404. doi: 10.1126/science.7521064. [DOI] [PubMed] [Google Scholar]
  9. Rickman L. S., Gordon D. M., Wistar R., Jr, Krzych U., Gross M., Hollingdale M. R., Egan J. E., Chulay J. D., Hoffman S. L. Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl lipid A, and squalane in malaria circumsporozoite protein vaccine. Lancet. 1991 Apr 27;337(8748):998–1001. doi: 10.1016/0140-6736(91)92659-p. [DOI] [PubMed] [Google Scholar]
  10. Rota J. S., Heath J. L., Rota P. A., King G. E., Celma M. L., Carabaña J., Fernandez-Muñoz R., Brown D., Jin L., Bellini W. J. Molecular epidemiology of measles virus: identification of pathways of transmission and implications for measles elimination. J Infect Dis. 1996 Jan;173(1):32–37. doi: 10.1093/infdis/173.1.32. [DOI] [PubMed] [Google Scholar]
  11. Sabin A. B. Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. J Infect Dis. 1985 Mar;151(3):420–436. doi: 10.1093/infdis/151.3.420. [DOI] [PubMed] [Google Scholar]
  12. Slack M. P. Invasive Haemophilus influenzae disease: the impact of Hib immunisation. J Med Microbiol. 1995 Feb;42(2):75–77. doi: 10.1099/00222615-42-2-75. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES